Rallybio (RLYB) Non-Current Assets (2020 - 2026)
Rallybio (RLYB) posted Non-Current Assets of $982000.0 for Q1 2026, down 2.58% sequentially from $1.0 million in Q4 2025, and up 63.12% YoY from $602000.0 in Q1 2025.
Rallybio (RLYB) Non-Current Assets (2020 - 2026) Analysis & Trends
Rallybio has reported Non-Current Assets for 7 years, with the latest figure at $982000.0 in Q1 2026.
- Quarterly Non-Current Assets rose 63.12% year-over-year to $982000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 42.45% YoY) and the FY2025 annual result came in at $1.0 million, up 277.53% from the prior year.
- Non-Current Assets retreated to $982000.0 in Q1 2026 per RLYB's latest filing, from $1.0 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.6 million in Q1 2022 and troughed at $267000.0 in Q4 2024.
- A 5-year average of $921117.6 and a median of $939000.0 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets sank 67.87% in 2024, then jumped 277.53% in 2025.
- Over 5 years, Non-Current Assets stood at $939000.0 in 2022, then decreased by 11.5% to $831000.0 in 2023, then tumbled by 67.87% to $267000.0 in 2024, then surged by 277.53% to $1.0 million in 2025, then declined by 2.58% to $982000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $982000.0, $1.0 million, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Rallybio | 94.32 Mn | 94.32 Mn | - | 810,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 810,000.00 |
| Mar 31, 2026 | 982,000.00 |
| Dec 31, 2025 | 1.01 Mn |
| Sep 30, 2025 | 1.03 Mn |
| Jun 30, 2025 | 738,000.00 |
| Mar 31, 2025 | 602,000.00 |
| Dec 31, 2024 | 267,000.00 |
| Sep 30, 2024 | 777,000.00 |
| Jun 30, 2024 | 995,000.00 |
| Mar 31, 2024 | 814,000.00 |
| Dec 31, 2023 | 831,000.00 |
| Sep 30, 2023 | 772,000.00 |
| Jun 30, 2023 | 742,000.00 |
| Mar 31, 2023 | 1.04 Mn |
| Dec 31, 2022 | 939,000.00 |
| Sep 30, 2022 | 1.24 Mn |
| Jun 30, 2022 | 1.31 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 1.32 Mn |
| Sep 30, 2021 | 1.47 Mn |